A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Phase 3 trial of seladelpar in PBC with inadequate response or unacceptable side effects with UDCA.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Overall, seladelpar was well tolerated.”
From Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor (2025) · cites this paper as [47]
In the citing paper
“As detailed earlier, pruritus was less frequent in seladelpar when compared to placebo.”
From Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor (2025) · cites this paper as [47]
In the citing paper
“There were no reported treatment-related deaths [16,23,47].”
From Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor (2025) · cites this paper as [47]
In the citing paper
“However, ALT and GGT were significantly decreased with seladelpar which indicates reduced hepatocellular injury [47].”
From Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor (2025) · cites this paper as [47]
In the citing paper
“Those on seladelpar 10 mg (n = 49) achieved −3.2 points while patients on placebo (n = 23) achieved −1.7 points (p = 0.005).”
From Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor (2025) · cites this paper as [47]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hirschfield, G. M., Beuers, U., Corpechot, C., Invernizzi, P., Jones, D., Marzioni, M., & Schramm, C. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.022 · Cited by 1,480
Self-citationA Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
Nevens, F., Andreone, P., Mazzella, G., Strasser, S. I., Bowlus, C., Invernizzi, P., Drenth, J. P. H., Pockros, P. J., Regula, J., Beuers, U., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509840 · Cited by 1,131
Self-citationInterleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice
Dillon, S. R., Sprecher, C., Hammond, A., Bilsborough, J., Rosenfeld-Franklin, M., Presnell, S. R., Haugen, H. S., Maurer, M., Harder, B., Johnston, J., et al. (2004) · Nature Immunology · doi:10.1038/ni1084 · Cited by 1,015
Lindor, K. D., Bowlus, C. L., Boyer, J., Levy, C., & Mayo, M. (2019) · Hepatology · doi:10.1002/hep.30145 · Cited by 913
Self-citationAlternative M2 Activation of Kupffer Cells by PPARδ Ameliorates Obesity-Induced Insulin Resistance
Odegaard, J. I., Ricardo-Gonzalez, R. R., Red Eagle, A., Vats, D., Morel, C. R., Goforth, M. H., Subramanian, V., Mukundan, L., Ferrante, A. W., & Chawla, A. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.04.003 · Cited by 847
Parés, A., Caballería, L., & Rodés, J. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.12.029 · Cited by 756
Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis
Corpechot, C., Abenavoli, L., Rabahi, N., Chrétien, Y., Andréani, T., Johanet, C., Chazouillères, O., & Poupon, R. (2008) · Hepatology · doi:10.1002/hep.22428 · Cited by 646
Self-citationA Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis
Corpechot, C., Chazouillères, O., Rousseau, A., Le Gruyer, A., Habersetzer, F., Mathurin, P., Goria, O., Potier, P., Minello, A., Silvain, C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714519 · Cited by 642
Self-citationThe 5-D itch scale: a new measure of pruritus
Elman, S., Hynan, L. S., Gabriel, V., & Mayo, M. J. (2010) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2009.09586.x · Cited by 540
Self-citationCorpechot, C., Chazouillères, O., & Poupon, R. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.02.031 · Cited by 460
Self-citation
Cited by
Items 101–200 of 277
The ethics of unlicensed therapy use in primary biliary cholangitis: a counter view
Jones, D. E. J., Mitchell-Thain, R., Culver, E. L., Dyson, J. K., Gish, R. G., Hansen, B. E., Hirschfield, G. M., Kowdley, K. V., Lleo, A., Kremer, A. E., et al. (2026) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-026-01179-8 · Cited by 3
Self-citationRisk factors and prediction for DILI in clinical practice
Björnsson, H. K., & Bjornsson, E. S. (2025) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2025.2468200 · Cited by 3
“However, in the subsequent phase III clinical trials cases of DILI were not observed [33,39].”
Díaz‐González, Á., Molera, C., Gómez-Domínguez, E., Muñoz‐Bartolo, G., Ampuero, J., Fernández‐Rodríguez, C., Quintero, J., Molina, E., Salcedo, M., Olveira, A., et al. (2025) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2026.502629 · Cited by 3
Bhushan, S. R., & Kowdley, K. V. (2025) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000001109 · Cited by 3
Self-citationPhase 3 Trials of Elafibranor and Seladelpar for Primary Biliary Cholangitis
Kowdley, K. V., Levy, C., & Jones, D. (2024) · New England Journal of Medicine · doi:10.1056/nejmc2403986 · Cited by 3
Self-citationMandea, M., Iacob, S. M., Ghioca, M. C., Gheorghe, C., & Gheorghe, L. S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14228240 · Cited by 5
Memon, A., Nadella, M., Emokpae, M. C., & Assis, D. N. (2025) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000001127 · Cited by 5
Ileal Bile Acid Transport Inhibitors for Cholestatic Pruritus: A Primer
Martins, A., & Levy, C. (2025) · Current Hepatology Reports · doi:10.1007/s11901-025-00699-2 · Cited by 4
Self-citationGerussi, A., Sebode, M., Nofit, E., Stoelinga, A., Bernasconi, D. P., Leburgue, A., Invernizzi, P., Schramm, C., van Hoek, B., TINIAKOS, D. G., et al. (2026) · Hepatology · doi:10.1097/hep.0000000000001793 · Cited by 3
Self-citationGerussi, A., Nofit, E., Bernasconi, D. P., Kroll, C., Groß, F., Schregel, I., Marini, A., Cristoferi, L., Malinverno, F., Papp, M., et al. (2025) · United European Gastroenterology Journal · doi:10.1002/ueg2.70134 · Cited by 4
Self-citationAli, N., Alotaibi, F. T., Babu, M. A., Singh, T., Alaseem, A. M., Tyagi, Y., & Bansal, N. (2026) · Archiv der Pharmazie · doi:10.1002/ardp.70190 · Cited by 6
Peverelle, M., Campbell, S. M.-A., Peverelle, J., Shah, S., Greener, K., Joshi, D., & Nayagam, J. S. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70666 · Cited by 6
Levy, C., Bowlus, C. L., Lawitz, E., Antunes, N., Miller, B., Shu, J., Zein, C. O., & Kowdley, K. V. (2026) · Liver International · doi:10.1111/liv.70630 · Cited by 3
Self-citationSebode, M., Bantel, H., Baumann, U., Bufler, P., Demir, M., Dold, L., Keitel, V., Klein, R., Kremer, A. E., Jansen, P. L., et al. (2026) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2769-2475 · Cited by 2
Self-citationGordon, S. C., Villamil, A., Jacobson, I. M., Lawitz, E., Younes, Z. H., Silveira, M. G., Bowlus, C. L., Drenth, J. P. H., Vierling, J. M., Morgera, U., et al. (2026) · Hepatology Communications · doi:10.1097/hc9.0000000000000918 · Cited by 3
Self-citationPan, S.-D., Xiong, C.-Y., Shen, Y.-J., Tian, J., Wang, Y., Wang, J., Wang, S., Li, F., Wang, L., Qiu, Q., et al. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i31.109828 · Cited by 2
Validation of PBC‐10 in Japanese patients with primary biliary cholangitis
Takeuchi, A., Abe, M., Furukawa, S., Namisaki, T., Takahashi, A., Abe, K., Kikuchi, K., Miura, R., Tachizawa, N., Asaoka, Y., et al. (2025) · Hepatology Research · doi:10.1111/hepr.14199 · Cited by 3
Liu, Y., Chen, L., Hao, W., Zhao, K., & Li, C. (2025) · International Journal of Immunopathology and Pharmacology · doi:10.1177/03946320251327621 · Cited by 3
Improving Primary Biliary Cholangitis Outcomes in the Evolving Landscape of Second‐Line Therapies
Scaravaglio, M., Ronca, V., Carbone, M., & Invernizzi, P. (2025) · Liver International · doi:10.1111/liv.70030 · Cited by 2
Self-citationPrimary Biliary Cholangitis in 2025: A New Frontier
Klatzkow, H. R., Bhavsar‐Burke, I., Pearson, M. M., & Wentworth, B. J. (2025) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003559 · Cited by 2
Popescu, I. R. (2025) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70948 · Cited by 3
Pruritus, Fatigue, Osteoporosis and Dyslipoproteinemia in Pbc Patients: A Clinician’s Perspective
Dražilová, S., Koky, T., Macej, M., Janíčko, M., Simkova, D., Tsedendamba, A., Комарова, С. Г., & Jarčuška, P. (2024) · Gastroenterology Insights · doi:10.3390/gastroent15020030 · Cited by 4
Sv, G., Proehl, S., Pratt, D., et al. (2026) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2026.01.011 · Cited by 2
Recent Advances in Primary Biliary Cholangitis Treatment
Das, T. S., & Vuppalanchi, R. (2025) · Clinics in Liver Disease · doi:10.1016/j.cld.2025.06.008 · Cited by 3
Maxwell, M., Deng, Y., Chen, B., Silveira, M. G., Boyer, J. L., & Assis, D. N. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70574 · Cited by 3
Prevalence and incidence of chronic kidney disease in patients with primary biliary cholangitis
Sousa, J. M., Rodríguez‐Tajes, S., Hernández‐Guerra, M., Casado, M., Berenguer, M., Castaño, Y. P., Morillas, R. M., García-Retortillo, M., García-Buey, L., Simón, M., et al. (2026) · Journal of Gastroenterology · doi:10.1007/s00535-026-02442-0 · Cited by 2
Song, J., Wang, Y., Guo, R., Wang, K. Y., Hu, Y., Cui, M., Wang, G., Hao, H., Wang, H., & Xu, X. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.178910 · Cited by 3
Early assessment of treatment response in primary biliary cholangitis: key to timely management
Koky, T., Dražilová, S., Janíčko, M., Toporcerová, D., Gazda, J., & Jarčuška, P. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-04138-w · Cited by 7
Tang, G., Zhang, J., Zhang, L., Xia, L., Tang, X., Chen, R., & Zhou, R. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1432814 · Cited by 3
Levy, C., Lleo, A., Martins, A., Scaravaglio, M., Bowlus, C. L., Carbone, M., Corpechot, C., Couto, C. A., Hansen, B. E., Hirschfield, G. M., et al. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.03.038 · Cited by 14
Self-citationIntegrative Hepatology: Enhancing overall health to manage liver disease
Lai, J. C., Tapper, E. B., & Tandon, P. (2025) · Hepatology · doi:10.1097/hep.0000000000001516 · Cited by 5
Huang, Z., Zhang, M., Zhang, X., Ge, Y., He, C., & Li, J. (2026) · Biomedicines · doi:10.3390/biomedicines14051101 · Cited by 1
Ruiu, A., Calabrese, M. P., Meschisi, P., Plebani, R., Maria, B., Lleò, A., & Ronca, V. (2026) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2026.106883 · Cited by 1
Recent advances in diagnosis and management of chronic cholestatic liver diseases: expert consensus
Mukewar, S. V. (2025) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20250288 · Cited by 1
Upadacitinib for refractory primary biliary cholangitis
Kolev, M., Möller, B., Berzigotti, A., & Semmo, N. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.03.004 · Cited by 1
Liao, W., Fu, S., Yang, A., & Yang, Y. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4863938 · Cited by 1
Kugiyama, Y., Abe, M., Namisaki, T., Yoshiji, H., Abe, K., Ohira, H., Shirahashi, R., Yokoyama, K., Fukunaga, A., Kawata, K., et al. (2025) · Hepatology Research · doi:10.1111/hepr.70035 · Cited by 1
Russo, M. W. (2025) · Digestive Diseases and Sciences · doi:10.1007/s10620-025-09177-7 · Cited by 1
(2026) · doi:10.3389/fphar.2026.1769883 · Cited by 1
“Overlap” Syndromes in Autoimmune Liver Disease
Tzadok, R., & Houri, I. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2026.04.008 · Cited by 1
Okoruwa, E. T., & Mayo, M. J. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2026.04.010 · Cited by 1
Self-citationJones, D. E., Combe, E., Knight, H., Laskier-Owens, V., Ren, S., Wright, T., Boing, E., & Pashley, A. (2026) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2025-0206 · Cited by 1
Implementation of a care bundle improves PBC management
Smith, R., Burke, L., Abbas, N., Aspinall, R., Thorburn, D., Heneghan, M. A., Yeoman, A. D., Leithead, J., Braniff, C., Mitchell-Thain, R., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101422 · Cited by 3
Abuelazm, M. T., Alsakarneh, S., Tanashat, M., Manasrah, A., Ibrahim, A. A., Parajuli, S., Eltaly, H., & Amin, A. M. (2025) · JGH Open · doi:10.1002/jgh3.70265 · Cited by 2
The role of Seladelpar in primary biliary cholangitis: a systematic review and meta-analysis
Ashraf, T., Abunada, O., Seerani, N., Ali, K., Muhammad, A., Mir, S. L., Shah, S. A. M., Hassaan, M., Kumar, V., Abbas, W., et al. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-03812-3 · Cited by 2
Seladelpar in primary biliary cholangitis
(2024) · doi:10.1038/s41575-024-00922-3 · Cited by 1
Elafibranor in the treatment of primary biliary cholangitis
Ergenç, İ., & Heneghan, M. A. (2025) · Future Rare Diseases · doi:10.1080/23995270.2025.2580910 · Cited by 2
Martins, A., & Levy, C. (2025) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000001076 · Cited by 3
Self-citationEditorial: UDCA Dosing in PBC – Between Guideline Adherence and Clinical Reality
Hernández-Évole, H., & Londoño, M. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70703 · Cited by 1
Gerussi, A., & Fornai, M. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108144 · Cited by 2
Bile acid signaling: from dynamic pool composition to inter-organ communication
Yang, F., Wei, T., Liu, K. L., Chu, H., & Yang, L. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1890710 · Cited by 3
Recompensation in Cirrhosis: Biomarkers and Strategies
Ramírez-Quesada, W. E., Alvarado‐Tápias, E., Shalaby, S., & Hernández–Gea, V. (2025) · Seminars in Liver Disease · doi:10.1055/a-2542-9930 · Cited by 2
Seladelpar: New hope for patients with primary biliary cholangitis
Nevzorova, Y. A., & Cubero, F. J. (2024) · Med · doi:10.1016/j.medj.2024.03.019 · Cited by 1
Stein, K., Hofmann, W. P., Franke, A., Petroff, D., Müller, T., Bantel, H., Günther, R., Denk, G., Reuken, P. A., Schattenberg, J. M., et al. (2025) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2721-1160 · Cited by 1
Self-citationLakshmanan, V., & Morris, L. (2025) · Cureus · doi:10.7759/cureus.94172 · Cited by 3
Emerging Therapeutics for Primary Biliary Cholangitis
Cho, E. J. (2025) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2025.045 · Cited by 1
Raja, A., Ahmed, M., Raja, S., Rahman, H. A. U., Kumar, M., Asghar, M. S., & Kumar, S. (2024) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001829 · Cited by 1
Feng, Z., Xie, J., Hou, D., Fu, Z., Sun, S., Liu, X., Sun, G., Zheng, R., Liu, L., Xu, Q., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03132 · Cited by 1
Autoimmune und genetisch-cholestatische Lebererkrankungen: die neuen Leitlinien
Sebode, M., Hudert, C. A., Lohse, A. W., & Bufler, P. (2025) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2462-8656 · Cited by 2
Single and Multiple Doses of Seladelpar Decrease Diurnal Markers of Bile Acid Synthesis in Mice
Cable, E. E., Stebbins, J. W., Johnson, J. D., Choi, Y., Song, J., Gatto, S., Onorato, M. T., & McWherter, C. A. (2025) · PPAR Research · doi:10.1155/ppar/5423221 · Cited by 1
Self-citationOptimizing Care in Primary Biliary Cholangitis: Current Treatments and the Second-Line Decision
Choi, G., Jesudian, A. B., & Saab, S. (2025) · Digestive Diseases and Sciences · doi:10.1007/s10620-025-09537-3 · Cited by 4
Cholestasis in hepatitis E virus infection
Kanda, T., Sasaki, R., Yokoo, T., Hayashi, K., Kamimura, H., Tsuchiya, A., & Terai, S. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i4.99899 · Cited by 1
Giorgio, C. D., Urbani, G., Massa, C., Marchianò, S., Biagioli, M., Bordoni, M., Lachi, G., Sensini, B., SORDO, R. D., Paniconi, F., et al. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000779 · Cited by 1
Year in Review: Selection of Best Papers in Gastroenterology and Hepatology 2024
Camilleri, M., & Dellon, E. S. (2025) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2025.06.001 · Cited by 1
Liver disease and general anesthesia: what the anesthesiologist needs to know
Flick, M., Sebode, M., Eichlseder, M., & Saugel, B. (2026) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000001648 · Cited by 1
Lessons From COBALT: Will the Bell Also Toll for Thee?
Vierling, J. M., & Pockros, P. J. (2024) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003061 · Cited by 1
Self-citationSeladelpar for the Treatment of Primary Biliary Cholangitis
Khoury, A., & Powell, J. (2025) · Annals of Pharmacotherapy · doi:10.1177/10600280251320069 · Cited by 2
Romeo, M., Nardo, F. D., Basile, C., Napolitano, C., Vaia, P., Martinelli, G., Gregorio, A. D., Puorto, L. D., Indipendente, M., Dallio, M., et al. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15120597 · Cited by 3
Silveira, I. B., Rezende, R. A. A., Neto, C. A. M. L., Rossi, Y. I., Leite, M. D. A. B. C., & Cançado, G. G. L. (2025) · Gastroenterology Insights · doi:10.3390/gastroent16030030 · Cited by 1
The role of the PPAR system in diabetic cardiovascular risk and beyond
Ruscica, M., Macchi, C., Corsini, A., & Sirtori, C. R. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000943 · Cited by 1
Liao, W., Fu, S., Yang, A., & Yang, Y. (2025) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848251370111 · Cited by 2
Peroxisome proliferator-activated receptors in metabolic and renal health: a comprehensive review
Vahora, N., Yathindra, M. R., James, D. M., Sharma, R., Panvalkar, A. S., Shyam, G., & Swathi, N. L. (2025) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20252817
Su, S., Yang, J., Luo, J., Yang, C., Li, C., Liu, X., Guo, G., & Han, Y. (2026) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-026-02154-8
Dichter, J. (2026) · The FASEB Journal · doi:10.1096/fj.202602616rr
Chidi, I. A., Ezeano, C., Williams, M. C., Boateng, S., Onyali, C. B., Obi, F., Odeyemi, J. O., Nwaneki, C. M., & Arora, G. (2025) · International Journal of Surgery Global Health · doi:10.1097/gh9.0000000000000572
Autoimmune Lebererkrankungen diagnostizieren und behandeln
Sebode, M. (2025) · Gastro-News · doi:10.1007/s15036-025-3947-1
Primär biliäre Cholangitis – Update zu Diagnostik, Risikostratifizierung und neuen Therapieoptionen
Herta, T., & Berg, T. (2025) · Die Innere Medizin · doi:10.1007/s00108-025-01988-0
A hepatic enigma: Pediatric presentation of primary biliary cholangitis
Kasturi, S., Schenker, R., Shillingford, N., & Yanni, G. S. (2026) · JPGN Reports · doi:10.1002/jpr3.70210
Primary biliary cholangitis review – new management strategies emerge
Gatley, E., Gogela, N. A., & Sonderup, M. W. (2025) · South African journal of gastroenterology and hepatology. · doi:10.36303/sajgh.2491
Treatment Goals for Primary Biliary Cholangitis, an Australian Perspective
Strasser, S. I., Thompson, A. J. V., Gupta, R., Lubel, J. S., French, J., Sacks, B., & Weltman, M. (2026) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70616
The Scientific Basis of Cholestatic Liver Disease and Its Symptom Complex
Nguyen, H. H., & Swain, M. G. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2026.04.001
Diagnostik und Therapie der Grunderkrankung bei Leberzirrhose
Lang‐Meli, J., & Neumann‐Haefelin, C. (2025) · Springer eBooks · doi:10.1007/978-3-662-70167-6_11
Advances in Management Strategies for Primary Biliary Cholangitis
Rojas-Amaris, N., Marenco‐Flores, A., Barba, R., Mendoza, R., Patwardhan, V. R., & Bonder, A. (2025) · Current Hepatology Reports · doi:10.1007/s11901-025-00700-y
Nuclear receptors as therapeutic targets in metabolic and cardiovascular disorders
Li, F., Chen, Q., Dai, Y., & Lu, L. (2025) · iScience · doi:10.1016/j.isci.2025.114042 · Cited by 1
Epidemiology, Pathogenesis and Treatment Progress of Primary Biliary Cholangitis
余, 兴. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.153599
Systemic pruritus as a neuroimmune disorder: Mechanistic insights and target‐driven therapy
Speeckaert, R., Speeckaert, M. M., Lapeere, H., & Lambert, J. (2026) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.70737
The emerging role of PPARs in primary biliary cholangitis
Palomer, X., Rodríguez‐Calvo, R., Mateo, S. G., Wahli, W., & Vázquez‐Carrera, M. (2026) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2026.05.008
Guo, M., Wu, Q., Deng, C.-H., Jiang, X., Wang, J. H., Zeng, C., Tan, X., Teng, F., Liu, Y., Zeng, Y., et al. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156767
Pemafibrate Improves Cholestatic Markers Regardless of the Presence of Primary Biliary Cholangitis
Tanigawa, R., Ueno, Y., Takahashi, H., Saito, A., Suganami, H., & Tanaka, A. (2026) · Hepatology Research · doi:10.1111/hepr.70244 · Cited by 1
Primary Biliary Cholangitis: The Evolving Therapeutic Landscape
Schonfeld, E. A., & Kumar, S. (2026) · Current Hepatology Reports · doi:10.1007/s11901-026-00741-x
Kennedy, C., Conroy, L., Millar, B., & de Gaetano, M. (2025) · Bleeding Thrombosis and Vascular Biology · doi:10.4081/btvb.2025.187
Sebode, M., & Lohse, A. W. (2026) · Die Gastroenterologie · doi:10.1007/s11377-026-01028-9
Bezafibrate for primary biliary cholangitis: A number needed to treat analysis
Werner, E., van de Vrie, M. A., van Hooff, M. C., Hansen, B. E., van der Meer, A. J., Abraham, S., Adang, R. P. R., Aktas, H., Alderlieste, Y. A., Aparicio-Pages, M. N., et al. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101926
Ronconi, G., Dondi, L., Ambrosio, N., Calabria, S., Maverna, G., Acciai, V., Buttiglione, V., Invernizzi, P., Gentilucci, U. V., Carbone, M., et al. (2026) · Global & Regional Health Technology Assessment · doi:10.33393/grhta.2026.3767
Self-citationMedikamentöse Therapie der Leberzirrhose
Schachteli, F., Uschner, F. E., Trebicka, J., & Brol, M. J. (2026) · Gastroenterologie up2date · doi:10.1055/a-2358-8821
Xiong, J., Zhang, Z., Zhang, Z., Yuan, M., Zhu, K., Wang, F., & Shi, L. (2026) · eGastroenterology · doi:10.1136/egastro-2026-100526
Metadata
- Authors
- Hirschfield, G. M., Bowlus, C. L., Mayo, M. J., Kremer, A. E., Vierling, J. M., Kowdley, K. V., Levy, C., Villamil, A., Ladrón de Guevara Cetina, A. L., Janczewska, E., Zigmond, E., Jeong, S.-H., Yilmaz, Y., Kallis, Y., Corpechot, C., Buggisch, P., Invernizzi, P., Londoño Hurtado, M. C., Bergheanu, S., Yang, K., Choi, Y.-J., Crittenden, D. B., & McWherter, C. A.
- Affiliations
- University Health Network (CA)
- From the Toronto Centre for Liver Disease, Division of Gastroenterology and Hepatology, University Health Network, Toronto General Hospital, Toronto (G.M.H.); the Division of Gastroenterology and Hepatology, University of California Davis School of Medicine, Sacramento (C.L.B.), and CymaBay Therapeutics, Newark (K.Y., Y.-J.C., D.B.C., C.A.M.) — both in California; the University of Texas Southwestern Medical School, Dallas (M.J.M.), and the Departments of Medicine and Surgery, Baylor College of Medicine, Houston (J.M.V.) — both in Texas; the Department of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland (A.E.K.); Liver Institute Northwest, Seattle (K.V.K.); the Division of Digestive Health and Liver Diseases, University of Miami, Miami (C.L.); the Liver Autoimmunity Unit, Hospital Italiano de Buenos Aires, Buenos Aires (A.V.); Centro de Investigación y Gastroenterología, Mexico City (A.L.L.G.C.); the Department of Basic Medical Sciences, Faculty of Publ...
- ORCID
- Hirschfield, Gideon M.
- Bowlus, Christopher L.
- Mayo, Marlyn J.
- Kremer, Andreas E.
- Vierling, John M.
- Kowdley, Kris V.
- Levy, Cynthia
- Villamil, Alejandra
- Janczewska, Ewa
- Zigmond, Ehud
- Jeong, Sook-Hyang
- Yilmaz, Yusuf
- Kallis, Yiannis
- Corpechot, Christophe
- Buggisch, Peter
- Invernizzi, Pietro
- Yang, Ke
- Choi, Yun-Jung
- Crittenden, Daria B.
- McWherter, Charles A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-02-29
- Volume
- 390
- Issue
- 9
- Pages
- 783-794
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4392015136
- Cited by
- 286
- References
- 42
- Citations by year
- 2026: 106 · 2025: 128 · 2024: 52
- FWCI
- 73.92
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- CymaBay Therapeutics
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- seladelpar, primary biliary cirrhosis, PPARδ agonist, ursodeoxycholic acid, biochemical response, alkaline phosphatase, pruritus
- MeSH terms
- Acetates, Administration, Oral, Alkaline Phosphatase, Bilirubin, Cholagogues and Choleretics, Double-Blind Method, Gastrointestinal Agents, Humans, Liver Cirrhosis, Biliary, Pruritus, Ursodeoxycholic Acid, Treatment Outcome, PPAR delta
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.